{
"id":"mk19_a_id_t48",
"number":48,
"bookId":"id",
"title":{
"__html":"Treatment of <i>Clostridioides difficile</i> Infection<sup>a</sup>"
},
"jsonContent":{
"type":"tag",
"tagName":"table",
"attrs":{
"className":"table"
},
"children":[
{
"type":"tag",
"tagName":"caption",
"attrs":{
},
"children":[
{
"type":"p",
"hlId":"fff129",
"children":[
{
"type":"tag",
"tagName":"b",
"attrs":{
"className":"table-number"
},
"children":[
{
"type":"tag",
"tagName":"span",
"attrs":{
},
"children":[
"Table 48. "
]
},
{
"type":"new-window-link",
"targetType":"table",
"targetId":"mk19_a_id_t48"
}
]
},
"Treatment of ",
{
"type":"tag",
"tagName":"i",
"attrs":{
},
"children":[
"Clostridioides difficile"
]
},
" Infection",
{
"type":"tag",
"tagName":"sup",
"attrs":{
},
"children":[
"a"
]
}
]
}
]
},
{
"type":"tag",
"tagName":"thead",
"attrs":{
},
"children":[
{
"type":"tag",
"tagName":"tr",
"attrs":{
},
"children":[
{
"type":"tag",
"tagName":"th",
"attrs":{
"rowSpan":"1",
"colSpan":"1"
},
"children":[
" ",
{
"type":"p",
"hlId":"180112",
"class":"col hd l",
"children":[
"Severity of Disease"
]
},
" "
]
},
{
"type":"tag",
"tagName":"th",
"attrs":{
"rowSpan":"1",
"colSpan":"1"
},
"children":[
" ",
{
"type":"p",
"hlId":"39db6b",
"class":"col hd l",
"children":[
"Treatment",
{
"type":"tag",
"tagName":"sup",
"attrs":{
},
"children":[
"b"
]
}
]
},
" "
]
}
]
}
]
},
{
"type":"tag",
"tagName":"tbody",
"attrs":{
},
"children":[
{
"type":"tag",
"tagName":"tr",
"attrs":{
"className":"group_1-1 row-odd"
},
"children":[
{
"type":"tag",
"tagName":"td",
"attrs":{
"rowSpan":"1",
"colSpan":"1"
},
"children":[
" ",
{
"type":"p",
"hlId":"b1f653",
"class":"cell txt l",
"children":[
"Nonsevere"
]
},
" "
]
},
{
"type":"tag",
"tagName":"td",
"attrs":{
"rowSpan":"1",
"colSpan":"1"
},
"children":[
" ",
{
"type":"p",
"hlId":"4d0f42",
"class":"cell txt l",
"children":[
"Fidaxomicin, 200 mg twice daily PO × 10 d (preferred)"
]
},
" ",
{
"type":"p",
"hlId":"fe7c4f",
"class":"cell txt l",
"children":[
"Vancomycin, 125 mg four times daily PO × 10 d (alternative)"
]
},
" ",
{
"type":"p",
"hlId":"1f08e1",
"class":"cell txt l",
"children":[
"If neither oral fidaxomicin or vancomycin is available (or both are contraindicated), metronidazole, 500 mg three times daily PO × 10-14 d"
]
},
" "
]
}
]
},
{
"type":"tag",
"tagName":"tr",
"attrs":{
"className":"group_1-2 row-even"
},
"children":[
{
"type":"tag",
"tagName":"td",
"attrs":{
"rowSpan":"1",
"colSpan":"1"
},
"children":[
" ",
{
"type":"p",
"hlId":"a6b2b9",
"class":"cell txt l",
"children":[
"Severe"
]
},
" "
]
},
{
"type":"tag",
"tagName":"td",
"attrs":{
"rowSpan":"1",
"colSpan":"1"
},
"children":[
" ",
{
"type":"p",
"hlId":"4d0f42",
"class":"cell txt l",
"children":[
"Fidaxomicin, 200 mg twice daily PO × 10 d (preferred)"
]
},
" ",
{
"type":"p",
"hlId":"687301",
"class":"cell txt l",
"children":[
"Vancomycin, 125 mg four times daily PO × 10 d (alternative) "
]
},
" "
]
}
]
},
{
"type":"tag",
"tagName":"tr",
"attrs":{
"className":"group_1-3 row-odd"
},
"children":[
{
"type":"tag",
"tagName":"td",
"attrs":{
"rowSpan":"1",
"colSpan":"1"
},
"children":[
" ",
{
"type":"p",
"hlId":"6d6ac9",
"class":"cell txt l",
"children":[
"Fulminant"
]
},
" "
]
},
{
"type":"tag",
"tagName":"td",
"attrs":{
"rowSpan":"1",
"colSpan":"1"
},
"children":[
" ",
{
"type":"p",
"hlId":"fb619b",
"class":"cell txt l",
"children":[
"Vancomycin, 500 mg four times daily PO or by NGT, plus metronidazole, 500 mg every 8 h IV"
]
},
" ",
{
"type":"p",
"hlId":"178399",
"class":"cell txt l",
"children":[
"When ileus is present, consideration of vancomycin PR at a dose of 500 mg in approximately 100 mL normal saline every 6 h"
]
},
" "
]
}
]
}
]
}
]
},
"footnotes":[
[
"IV = intravenously; NGT = nasogastric tube; PO = by mouth; PR = per rectum."
],
[
{
"type":"tag",
"tagName":"sup",
"attrs":{
},
"children":[
"a"
]
},
"Initial presentation."
],
[
{
"type":"tag",
"tagName":"sup",
"attrs":{
},
"children":[
"b"
]
},
"Adjunctive bezlotoxumab may be considered for patients with a primary infection and other risks for infection recurrence, but implementation depends on available resources and logistics for intravenous administration. Additional risk factors for recurrence include age >65 years, immunosuppression (per history or use of immunosuppressive therapy), and severe disease on presentation."
]
]
}